GSK Gross Margin 2010-2023 | GSK
Current and historical gross margin for GSK (GSK) over the last 10 years. The current gross profit margin for GSK as of March 31, 2023 is %.
| GSK Gross Margin Historical Data |
| Date |
TTM Revenue |
TTM Gross Profit |
Gross Margin |
| 2023-03-31 |
$31.59B |
$22.37B |
70.79% |
| 2022-12-31 |
$36.27B |
$24.45B |
67.42% |
| 2022-09-30 |
$43.90B |
$28.38B |
64.65% |
| 2022-06-30 |
$47.19B |
$30.54B |
64.72% |
| 2022-03-31 |
$49.80B |
$32.32B |
64.89% |
| 2021-12-31 |
$46.91B |
$30.96B |
65.99% |
| 2021-09-30 |
$45.57B |
$30.43B |
66.78% |
| 2021-06-30 |
$44.22B |
$29.34B |
66.35% |
| 2021-03-31 |
$42.37B |
$28.02B |
66.13% |
| 2020-12-31 |
$43.78B |
$28.76B |
65.68% |
| 2020-09-30 |
$43.78B |
$28.72B |
65.60% |
| 2020-06-30 |
$44.19B |
$28.85B |
65.30% |
| 2020-03-31 |
$44.77B |
$29.08B |
64.96% |
| 2019-12-31 |
$43.10B |
$27.95B |
64.86% |
| 2019-09-30 |
$38.25B |
$24.84B |
64.94% |
| 2019-06-30 |
$37.22B |
$24.38B |
65.49% |
| 2019-03-31 |
$37.13B |
$24.53B |
66.07% |
| 2018-12-31 |
$41.14B |
$27.47B |
66.77% |
| 2018-09-30 |
$44.61B |
$30.00B |
67.26% |
| 2018-06-30 |
$44.33B |
$29.69B |
66.97% |
| 2018-03-31 |
$43.74B |
$28.90B |
66.06% |
| 2017-12-31 |
$38.90B |
$25.58B |
65.74% |
| 2017-09-30 |
$38.21B |
$25.15B |
65.84% |
| 2017-06-30 |
$37.84B |
$24.95B |
65.92% |
| 2017-03-31 |
$37.85B |
$25.26B |
66.73% |
| 2016-12-31 |
$37.63B |
$25.09B |
66.68% |
| 2016-09-30 |
$37.82B |
$24.54B |
64.89% |
| 2016-06-30 |
$37.41B |
$24.03B |
64.23% |
| 2016-03-31 |
$37.06B |
$23.66B |
63.83% |
| 2015-12-31 |
$36.65B |
$23.11B |
63.06% |
| 2015-09-30 |
$36.35B |
$23.44B |
64.50% |
| 2015-06-30 |
$35.97B |
$23.43B |
65.12% |
| 2015-03-31 |
$36.42B |
$24.05B |
66.03% |
| 2014-12-31 |
$37.35B |
$25.28B |
67.69% |
| 2014-09-30 |
$39.27B |
$26.37B |
67.14% |
| 2014-06-30 |
$40.67B |
$27.55B |
67.74% |
| 2014-03-31 |
$41.36B |
$28.11B |
67.97% |
| 2013-12-31 |
$41.79B |
$28.36B |
67.86% |
| 2013-09-30 |
$41.34B |
$28.74B |
69.52% |
| 2013-06-30 |
$41.34B |
$28.72B |
69.48% |
| 2013-03-31 |
$41.38B |
$28.64B |
69.21% |
| 2012-12-31 |
$42.22B |
$29.71B |
70.36% |
| 2012-09-30 |
$42.43B |
$30.16B |
71.08% |
| 2012-06-30 |
$43.22B |
$31.02B |
71.76% |
| 2012-03-31 |
$43.96B |
$32.23B |
73.31% |
| 2011-12-31 |
$43.79B |
$32.02B |
73.13% |
| 2011-09-30 |
$44.43B |
$32.39B |
72.90% |
| 2011-06-30 |
$43.69B |
$31.91B |
73.05% |
| 2011-03-31 |
$41.94B |
$30.37B |
72.42% |
| 2010-12-31 |
$42.68B |
$30.94B |
72.49% |
| 2010-09-30 |
$44.26B |
$32.34B |
73.08% |
| 2010-06-30 |
$44.80B |
$32.91B |
73.46% |
| 2010-03-31 |
$46.13B |
$34.09B |
73.91% |
| 2009-12-31 |
$44.58B |
$33.02B |
74.07% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$69.205B |
$36.279B |
|
GSK plc is a biopharma company. Its vaccine portfolio protects people from meningitis, shingles, flu, polio, measles and many more. GSK plc, formerly known as GLAXOSMITHKLINE, is based in Brentford, the United Kingdom.
|
